For in situ characterization of breast cancer stem cells, we did not use the combination of markers CD44+CD24−/low, [18, 27] since this combination of positive and negative markers, currently used in cytometry, is more difficult to translate into in situ tissue analyses and cell counts. This evidence concerns the gene CD44 and breast carcinoma.